Continuous glucose monitoring has become a cornerstone of modern diabetes management, enabling real-time glucose tracking that drives better clinical decision-making and empowers patients. ADA 2027 will feature an extensive track on CGM technology, encompassing new device data, clinical outcomes research, and implementation science.
Remarkable advances in CGM sensor accuracy, wearability, and longevity continue to reshape diabetes care. At ADA 2027, attendees can expect presentations on next-generation CGM devices featuring factory calibration, extended wear times exceeding two weeks, and seamless integration with insulin pumps and automated delivery algorithms. Fully implantable sensors with multi-month longevity represent an exciting frontier.
A major theme at ADA 2027 will be the expansion of CGM use beyond type 1 diabetes into the vastly larger type 2 diabetes population. New evidence on the benefits of real-time CGM in non-insulin-treated type 2 diabetes, including improvements in HbA1c, time-in-range, and quality of life, will be presented. Data on CGM use in elderly and hospitalized patients are also expected.
Non-invasive glucose monitoring remains a highly anticipated area of research. ADA 2027 may feature early-stage data on optical and electrochemical sensing modalities seeking to eliminate the need for interstitial sensor insertion. While no fully validated non-invasive CGM has yet reached clinical use, the pace of innovation in this area continues to accelerate.
June 2027
ADA 2027 Abstract Submission Guidelines
June 2027
